/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its groundbreaking work in antiviral therapies. Valued at a market cap of $108 billion, Gilead's innovative portfolio delivers cutting-edge treatments that improve patient outcomes in areas such as HIV, hepatitis, and cancer. The company is set to announce its fiscal Q3 earnings results after the market closes on Wednesday, November 6.
Ahead of the event, analysts expect GILD to report a profit of $1.64 per share, down 28.4% from $2.29 per share in the year-ago quarter. The company surpassed Wall Street’s bottom-line estimates in three quarters and missed on another occasion in the last four quarters.